Mucosta
(Rebamipide)PreclinicalSmall molecule
OtsukaRebamipide is used to treat dry eye disease by helping the eye produce more natural tears and protecting the eye's surface from damage.[1] Mucosta is currently being investigated across 7 indications[3], with its most advanced program in Preclinical.[1]
Mucosta is one of 67 small molecule programs targeting Dry Eye Syndrome. It is currently in Preclinical.
7
Indications
26
Total Trials
1
Active Trials
66
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
28 competitors in Peptic Ulcer
#DrugCompanyPhaseTrials
1Prevacid
TakedaApproved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Bayer Aspirin
BayerApproved
Protonix
WWyeth-Lederle Vaccines
Approved
Cytotec
PfizerApproved
Dexilant
TakedaApproved
Takecab
PPhathom Pharmaceuticals, Inc.
Approved
Aciphex
Akero TherapeuticsApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Zantac 150
CChattem
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Gastric Ulcer3 trials
Rheumatoid Arthritis2 trials
Chronic Gastritis2 trials
Interaction2 trials
15 more indications
Prevention1 trial
Non-steroidal Anti-inflammatory Drugs1 trial
Atrial Fibrillation1 trial
Ulcerative Colitis1 trial
Dyspepsia1 trial
Esophagitis1 trial
Combination Therapy1 trial
Rheumatoid Arthritis (RA)1 trial
Keratoconjunctivitis sicca1 trial
Unspecified1 trial
h.Pylori Ttt With Rebamipide
Unknown status·—··NCT04550858·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rebamipide. EMBL-EBI & Wellcome Sanger Institute.
- [4]